Vimpat 100mg 1 Tablet
₱115.75
IMPORTANT NOTICE:
For this product, a doctor's prescription is required. Please do not forget to attach a copy of your valid prescription(.jpeg, bmp, gif, jpg, jpeg, jpe, jif, jfif, jfi, png, wbmp, xbm, tiff format). After you have placed your order, our pharmacist will be in touch to confirm your order and validate your prescription. Please present the original copy of your prescription upon the arrival of your order.
An item like loose capsule/tablets, ampules, vials, and refrigerated items is not subject for merchandise return or exchange upon completing the purchase.
| Brand Name | VIMPAT 100MG |
| Generic Name | Lacosamide |
| Strength | 100mg Film-coated Tablet |
| Dosage Form | Tablet |
| Class Name | Antiepileptic |
| Indication/Usage | Lacosamide (Vimpat) is indicated as: • monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 16 years and older • adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. |
| Dosage and Administration | • Monotherapy Initial monotherapy Patients not currently being treated with antiepileptic drugs may have monotherapy initiated with lacosamide (Vimpat). The recommended starting dose is 100 mg twice a day (200 mg/day) which should be increased to a therapeutic dose of 150 mg twice a day (300 mg/day) after one week. Depending on response and tolerability, the dose can be further increased at weekly interval by 50 mg twice a day (100 mg/day), to a maximum recommended maintenance daily dose of 200 mg twice a day (400 mg/day). Conversion to monotherapy For patients who will convert to lacosamide (Vimpat) monotherapy, the recommended starting dose is 100 mg twice a day (200 mg/day) which should be increased to a therapeutic dose of 150 mg twice a day (300 mg/day) after one week. Depending on response and tolerability, the dose can be further increased at weekly interval by 50 mg twice a day (100 mg/day), to a maximum recommended maintenance daily dose of 200 mg twice a day (400 mg/day). The recommended maintenance daily dose should be maintained for at least 3 days before initiating conversion to lacosamide monotherapy. A gradual withdrawal of the concomitant antiepileptic drug over at least 6-weeks is recommended. If the patient is on more than one antiepileptic drug, the antiepileptic drugs should be withdrawn sequentially. Safety and efficacy of Lacosamide (Vimpat) have not been established for simultaneous conversion to monotherapy from two or more concomitant antiepileptic drugs. • Adjunctive therapy The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response and tolerability, the maintenance dose can be further increased by 50 mg twice a day every week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). Initiation of lacosamide treatment with a loading dose Lacosamide (Vimpat) treatment (i.e. for adjunctive therapy, initial monotherapy and conversion to monotherapy) may also LACOSAMIDE be initiated with a single loading dose of 200 mg, followed approximately 12 hours later by a 100 mg twice daily (200 mg/day) maintenance dose regimen. A loading dose should be administered under medical supervision with consideration of the lacosamide pharmacokinetics (see section Pharmacokinetic properties) and the potential for increased incidence of CNS adverse reactions (see section Undesirable effects). Administration of a loading dose has not been studied in acute conditions such as status epilepticus. Depending on response and tolerability, the maintenance dose can be further increased by 50 mg twice a day every week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). |
| Warning and Precautions | Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine |
| Contraindication | Hypersensitivity to the active substance or to any of the excipients. |
| Requires prescription? | Yes |
| Storage Conditions | Store at temperatures not exceeding 30°C, away from direct heat and sunlight |
| Manufacturer | Aesica Pharmaceuticals GmbH |
| Regulatory Classification | Prescription Drug |
Related Products
Vimpat 50mg 1 Tablet
₱61.25
IMPORTANT NOTICE:For this product, a doctor's prescription is required. Please do not forget to attach a copy of your valid prescription(.jpeg, bmp, gif, jpg, jpeg, jpe, jif, jfif, jfi, png, wbmp,...
